Edoxaban

A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism

Kara A. Kubli, Jessica A. Snead, Angela Cheng-Lai

Research output: Contribution to journalArticle

Abstract

Warfarin has been a highly prevalent agent for over 70 years; however, its use has been limited by drug-drug interactions, adverse events, and the need for frequent monitoring. To minimize these complications, several non-vitamin K oral anticoagulants have been approved, including the latest agent, edoxaban. Edoxaban is a factor Xa inhibitor approved for prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Edoxaban was largely studied in the ENGAGE AF-TIMI 48 and Hokusai-VTE trials, both showing non-inferiority when compared to warfarin. Similar to other oral anticoagulants, the most serious adverse effects of edoxaban are related to bleeding. However, there are currently no approved reversal agents. Andexanet alfa and ciraparantag are the latest agents being studied for reversal. This article provides an overview of the safety and efficacy along with the advantages and disadvantages of edoxaban.

Original languageEnglish (US)
JournalCardiology in Review
DOIs
StateAccepted/In press - Mar 14 2016

Fingerprint

Venous Thromboembolism
Atrial Fibrillation
Warfarin
Anticoagulants
Embolism
Drug Interactions
Stroke
edoxaban
Factor Xa Inhibitors
Hemorrhage
Safety
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Edoxaban : A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism. / Kubli, Kara A.; Snead, Jessica A.; Cheng-Lai, Angela.

In: Cardiology in Review, 14.03.2016.

Research output: Contribution to journalArticle

@article{3db11c1da8a240ac88b32f191841c4cf,
title = "Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism",
abstract = "Warfarin has been a highly prevalent agent for over 70 years; however, its use has been limited by drug-drug interactions, adverse events, and the need for frequent monitoring. To minimize these complications, several non-vitamin K oral anticoagulants have been approved, including the latest agent, edoxaban. Edoxaban is a factor Xa inhibitor approved for prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Edoxaban was largely studied in the ENGAGE AF-TIMI 48 and Hokusai-VTE trials, both showing non-inferiority when compared to warfarin. Similar to other oral anticoagulants, the most serious adverse effects of edoxaban are related to bleeding. However, there are currently no approved reversal agents. Andexanet alfa and ciraparantag are the latest agents being studied for reversal. This article provides an overview of the safety and efficacy along with the advantages and disadvantages of edoxaban.",
author = "Kubli, {Kara A.} and Snead, {Jessica A.} and Angela Cheng-Lai",
year = "2016",
month = "3",
day = "14",
doi = "10.1097/CRD.0000000000000104",
language = "English (US)",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Edoxaban

T2 - A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism

AU - Kubli, Kara A.

AU - Snead, Jessica A.

AU - Cheng-Lai, Angela

PY - 2016/3/14

Y1 - 2016/3/14

N2 - Warfarin has been a highly prevalent agent for over 70 years; however, its use has been limited by drug-drug interactions, adverse events, and the need for frequent monitoring. To minimize these complications, several non-vitamin K oral anticoagulants have been approved, including the latest agent, edoxaban. Edoxaban is a factor Xa inhibitor approved for prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Edoxaban was largely studied in the ENGAGE AF-TIMI 48 and Hokusai-VTE trials, both showing non-inferiority when compared to warfarin. Similar to other oral anticoagulants, the most serious adverse effects of edoxaban are related to bleeding. However, there are currently no approved reversal agents. Andexanet alfa and ciraparantag are the latest agents being studied for reversal. This article provides an overview of the safety and efficacy along with the advantages and disadvantages of edoxaban.

AB - Warfarin has been a highly prevalent agent for over 70 years; however, its use has been limited by drug-drug interactions, adverse events, and the need for frequent monitoring. To minimize these complications, several non-vitamin K oral anticoagulants have been approved, including the latest agent, edoxaban. Edoxaban is a factor Xa inhibitor approved for prevention of stroke/systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Edoxaban was largely studied in the ENGAGE AF-TIMI 48 and Hokusai-VTE trials, both showing non-inferiority when compared to warfarin. Similar to other oral anticoagulants, the most serious adverse effects of edoxaban are related to bleeding. However, there are currently no approved reversal agents. Andexanet alfa and ciraparantag are the latest agents being studied for reversal. This article provides an overview of the safety and efficacy along with the advantages and disadvantages of edoxaban.

UR - http://www.scopus.com/inward/record.url?scp=84961223819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961223819&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000104

DO - 10.1097/CRD.0000000000000104

M3 - Article

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

ER -